A Biocompatible Hydrogen‐Bonded Organic Framework (HOF) as Sonosensitizer and Artificial Enzyme for In‐Depth Treatment of Alzheimer's Disease

Abstract Current phototherapeutic approaches for Alzheimer's disease (AD) exhibit restricted clinical outcomes due to the limited physical penetration and comprised brain microenvironment of noninvasive nanomedicine. Herein, a hydrogen‐bonded organic framework (HOF) based sonosensitizer is designed and synthesized. Mn‐TCPP, a planar molecule where Mn 2+ ion is chelated in the core with a large p‐conjugated system and 4 carboxylate acid groups, has been successfully used as building blocks to construct an ultrasound‐sensitive HOF (USI‐MHOF), which can go deep in the brain of AD animal models. The both in vitro and in vivo studies indicate that USI‐MHOF can generate singlet oxygen ( 1 O 2 ) and oxidize β‐amyloid (Aβ) to inhibit aggregation, consequently attenuating Aβ neurotoxicity. More intriguingly, USI‐MHOF exhibits catalase (CAT)‐ and superoxide dismutase (SOD)‐like activities, mitigating neuron oxidative stress and reprograming the brain microenvironment. For better crossing the blood‐brain barrier (BBB), the peptide KLVFFAED (KD8) has been covalently grafted to USI‐MHOF for improving BBB permeability and Aβ selectivity. Further, in vivo experiments demonstrate a significant reduction of the craniocerebral Aβ plaques and improvement of the cognition deficits in triple‐transgenic AD (3×Tg‐AD) mice models following deep‐penetration ultrasound treatment. The work provides the first example of an ultrasound‐responsive biocompatible HOF as non‐invasive nanomedicine for in‐depth treatment of AD.